ArticlePharmacogenomics
Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".
Article in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMany people with major depressive disorder (MDD) undergo a lengthy process of trial-and-error before finding a medication that works well for them. Pharmacogenomic (PGx) testing for MDD can help find a suitable antidepressant faster. However, concerns about health equity, and data privacy and security need to be considered before implementing the test.
methodsIn Fall 2024, 30 individuals attended a four-day public deliberation in Vancouver, British Columbia (BC) to provide direction on implementing PGx testing for MDD in BC's publicly funded healthcare system. Participants were recruited to represent a diversity of perspectives and experiences of British Columbians. Information supports included expert speakers and a background booklet. Event transcripts were analyzed using thematic analysis (both inductive and reflexive), while also accounting for participants' knowledge gains over time.
resultsParticipants adopted four policy-relevant positions on implementation: 1) PGx test results should be treated like other lab results; 2) stored in electronic medical records; 3) shared with patients and healthcare professionals in the circle of care; and 4) education about the test will facilitate its widespread use.
conclusionParticipants' positions represent informed, civic-minded, and policy-relevant priorities for the acceptable adoption of PGx testing for MDD in the BC healthcare system and elsewhere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.